We have found that Akt signaling contributes to some of the more notable abnormalities in tumor vascular itroma. Those vascular abnormalities include the propensity for excessive vascular permeability leading to tissue edema and sluggish blood flow, extravasation of fibrin and other matrix proteins that alter the extracellular microenvironment, and the trafficking of inflammatory cells in and out of the tumor-associated vasculature. In addition, we also showed that rapamycin is an effective inhibitor of Akt signaling in the tumor stroma. This grant application has two major goals: (1) to study rapamycin's effects on the tumor stroma and to determine the i.npact of the anti-stromal effects of rapamycin on its anti-tumor efficacy. Both vascular and nonvascular stroma will be studied. (2) to investigate the contribution to angiogenesis by key molecules in the Akt-mTOR pathway that may be critical for the observation effects of rapamycin.
Aim 1 is focused on dentification of the vessel targets of rapamycin.
Aim 2 is designed to explore the effects of rapamycin on the non-vascular tumor stroma Aim 3 investigates rapamycin inhibition of tumor cell trafficking across the endothelium in metastasis. In addition to examing rapamycin's effects, all three aims contain some investigations of individual molecules in the Akt-mTor pathway. A particular focus is proposed to examine Akt isoforms and the TORCH feedback to Akt in the regulation of angiogenesis and endothelial trafficking in order to better understand the key regulatory molecules that are affected by rapamycin to mediate the observed anti-stromal phenotypes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA092644-10
Application #
8459035
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$136,019
Indirect Cost
$43,074
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Skibinski, Adam; Breindel, Jerrica L; Prat, Aleix et al. (2014) The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep 6:1059-72
Lin, Chi-Iou; Merley, Anne; Sciuto, Tracey E et al. (2014) TM4SF1: a new vascular therapeutic target in cancer. Angiogenesis 17:897-907
Chin, Y Rebecca; Yoshida, Taku; Marusyk, Andriy et al. (2014) Targeting Akt3 signaling in triple-negative breast cancer. Cancer Res 74:964-73
Chin, Y Rebecca; Yuan, Xin; Balk, Steven P et al. (2014) PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov 4:942-55
Phillips, Sarah; Prat, Aleix; Sedic, Maja et al. (2014) Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Reports 2:633-47
Lin, Chi-Iou; Lau, Chun-Yee; Li, Dan et al. (2014) Nanopodia--thin, fragile membrane projections with roles in cell movement and intercellular interactions. J Vis Exp :
Rowe, Glenn C; Raghuram, Srilatha; Jang, Cholsoon et al. (2014) PGC-1? induces SPP1 to activate macrophages and orchestrate functional angiogenesis in skeletal muscle. Circ Res 115:504-17
Elloul, Sivan; Kedrin, Dmitriy; Knoblauch, Nicholas W et al. (2014) The adherens junction protein afadin is an AKT substrate that regulates breast cancer cell migration. Mol Cancer Res 12:464-76
Kazerounian, Shiva; Gerald, Damien; Huang, Minzhou et al. (2013) RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis. Cancer Res 73:50-61
Arendt, Lisa M; McCready, Jessica; Keller, Patricia J et al. (2013) Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis. Cancer Res 73:6080-93

Showing the most recent 10 out of 100 publications